DCOY Decoy Therapeutics Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 11
- List Date
- 2015-01-29
- CIK
- 0001615219
- Next Earnings
- 2026-11-13
- Headquarters
- Houston, TX
- Homepage
- https://www.decoytx.com
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery an…
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '26 | Avg |
|---|---|---|
| Jan | 0.12% | 0.12% |
| Feb | -5.40% | -5.40% |
| Mar | -17.67% | -17.67% |
| Apr | -4.27% | -4.27% |
| May | 51.19% | 51.19% |
| Jun | -14.00% | -14.00% |
| Jul | -43.70% | -43.70% |
| Aug | -29.72% | -29.72% |
| Sep | -35.62% | -35.62% |
| Oct | -50.39%* | -50.39% |
| Nov | -- | -- |
| Dec | -- | -- |
| Total | -87.73% | -87.73% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary Overall assessment: BEARISH (Confidence level: 8/10) Key drivers and primary risks: * Bearish momentum signals from MACD and RSI * Weak trend indicators (ADX/DMI) suggesting a downtrend regime * High volatility and beta, indicating increased risk * Lack of recent news sentiment impact
Recent news sentiment impact: No recent news available, which reduces the impact on stock price movements.
Technical Analysis Trend Direction: Short-term (1-4 weeks): BEARISH Medium-term (1-3 months): NEUTRAL Long-term (3-12 months): UNTRENDING
Support/Resistance Levels: * Key resistance level: $3.26 (SMA 20) * Key support level: $2.58 (Bollinger Band Lower)
Momentum Signals: * RSI interpretation: Oversold (27.53), potential buy signal * MACD signal: Bearish, indicating further price decline * Bollinger Bands position: Neutral, with no clear breakout or mean reversion
Volume Analysis: * Volume trends: Increased volume on recent price declines, suggesting institutional interest * Institutional interest signals: OBV and On-Balance Volume indicate selling pressure
News & Sentiment Analysis Recent Headlines Summary: No recent news available
Sentiment Assessment: Neutral (No sentiment data available)
Catalyst Identification: No upcoming events or earnings announcements
Market Narrative: Lack of recent news reduces market narrative impact on technical signals.
Risk & Volatility Assessment Beta Interpretation: High risk relative to market (beta 2.33)
Volatility Regime: Current volatility is high compared to historical levels (HV30 102.3%)
Options Market Signals: * IV rank: N/A * Put/call ratios: N/A * Unusual activity: No unusual options activity detected
Downside Protection: * Support level: $2.58 (Bollinger Band Lower) * Risk management considerations: Stop-loss levels should be set below $2.58 to manage potential losses.
Market Context & Positioning Sector Performance: Relative strength vs sector/market neutral
Institutional Activity: Volume patterns suggest institutional selling pressure
Correlation Analysis: Stock moves more than market (beta 2.33), indicating high risk and volatility
Relative Valuation: Position within trading range, with no clear buy or sell signal.
Key Levels & Action Items Critical Price Levels: * Resistance level: $3.26 (SMA 20) * Support level: $2.58 (Bollinger Band Lower)
Breakout/Breakdown Levels: * Breakout level: $3.93 (Bollinger Band Upper) * Breakdown level: $2.26 (Lower Bollinger Band)
Time-Sensitive Catalysts: No upcoming events or earnings announcements
Risk Management: Stop-loss levels should be set below $2.58 to manage potential losses.
This comprehensive analysis highlights the bearish momentum and weak trend indicators, suggesting a downtrend regime. The lack of recent news sentiment impact reduces market narrative influence on technical signals. High volatility and beta indicate increased risk, making it essential to set stop-loss levels below the support level ($2.58).
DCOY Options Activity & IV Rank
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
Risk Metrics
Analysis Details
Data Points: 200
Period: 252 trading days
High volatility - stock moves more than market
DCOY Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
DCOY Insider Trading (Form 4)
Latest: 2026-09-02| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | Jonathan I Lieber | Director | Award (A) | +2,000 | — | EDGAR | |
| 2026-09-02 | Paul Lammers | Director | Award (A) | +2,000 | — | EDGAR | |
| 2026-09-02 | Peter Klaus Marschel | Chief Business Officer | Award (A) | +3,900 | — | EDGAR | |
| 2026-09-02 | Barbara Louise Hibner | Chief Scientific Officer | Award (A) | +4,216 | — | EDGAR | |
| 2026-09-02 | Patricia G. Gauthier | Director | Award (A) | +2,000 | — | EDGAR | |
| 2026-09-02 | William K. McVicar | Director | Award (A) | +3,000 | — | EDGAR | |
| 2026-09-02 | Arnold C Hanish | Director | Award (A) | +3,000 | — | EDGAR | |
| 2026-09-02 | Mark J Rosenblum | Chief Financial Officer | Award (A) | +9,682 | — | EDGAR | |
| 2026-09-02 | Tess Burleson | Director | Award (A) | +2,000 | — | EDGAR | |
| 2026-09-02 | Frederick Pierce II | Chief Executive Officer | Award (A) | +33,455 | — | EDGAR |
DCOY Insider Holdings
10 insiders · @ $0.92| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Frederick Pierce II | Chief Executive Officer | 34,844 | $32.1K | $0 | 1 | 2026-09-02 |
| 2 | Mark J Rosenblum | Chief Financial Officer | 11,363 | $10.5K | $0 | 1 | 2026-09-02 |
| 3 | Barbara Louise Hibner | Chief Scientific Officer | 4,216 | $3.9K | $0 | 1 | 2026-09-02 |
| 4 | Peter Klaus Marschel | Chief Business Officer | 3,900 | $3.6K | $0 | 1 | 2026-09-02 |
| 5 | Arnold C Hanish | Director | 3,418 | $3.1K | $0 | 1 | 2026-09-02 |
| 6 | William K. McVicar | Director | 3,002 | $2.8K | $0 | 1 | 2026-09-02 |
| 7 | Jonathan I Lieber | Director | 2,002 | $1.8K | $0 | 1 | 2026-09-02 |
| 8 | Tess Burleson | Director | 2,002 | $1.8K | $0 | 1 | 2026-09-02 |
| 9 | Paul Lammers | Director | 2,001 | $1.8K | $0 | 1 | 2026-09-02 |
| 10 | Patricia G. Gauthier | Director | 2,000 | $1.8K | $0 | 1 | 2026-09-02 |
DCOY Board & Officers
As of SEC filings through Sep 2, 2026Directors 6
- William K. McVicar · listed since Jan 2018
- Arnold C Hanish · since Jul 19, 2019
- Paul Lammers · since Jul 19, 2019
- Tess Burleson · since Jul 19, 2019
- Jonathan I Lieber · since Jun 19, 2020
- Patricia G. Gauthier · since Jul 14, 2026
Officers 4
- Frederick Pierce II · Chief Executive Office · since Nov 12, 2025
- Mark J Rosenblum · Exec VP Finance, CFO · listed since Feb 2020
- Barbara Louise Hibner · Chief Scientific Officer · since Nov 12, 2025
- Peter Klaus Marschel · Chief Business Officer · since Nov 12, 2025
Changes in the last 10 years (31)
| Jul 14, 2026 | Patricia G. Gauthier became a director |
| Nov 12, 2025 | Peter Klaus Marschel became Chief Business Officer |
| Nov 12, 2025 | Frederick Pierce II became Chief Executive Office |
| Nov 12, 2025 | Barbara Louise Hibner became Chief Scientific Officer |
| Feb 20, 2024 | The company announced the departure of David J. Arthur from the board in an SEC filing |
| Feb 20, 2024 | The company announced the departure of David J. Arthur as Chief Executive Officer in an SEC filing |
| Jun 19, 2020 | Jonathan I Lieber became a director |
| Feb 13, 2020 | Mark J Rosenblum listed as Exec VP Finance, CFO (previously Exec VP Finance, Interim CFO) in SEC filings |
| Sep 13, 2019 | Scott Jordan listed as Chief Business Officer (previously Chief Financial Officer) in SEC filings |
| Sep 12, 2019 | William K. McVicar no longer listed as President and CEO in SEC filings |
| Sep 10, 2019 | Mark J Rosenblum became Exec VP Finance, Interim CFO |
| Jul 19, 2019 | Tess Burleson became a director |
| Jul 19, 2019 | Scott Jordan became Chief Financial Officer |
| Jul 19, 2019 | Paul Lammers became a director |
| Jul 19, 2019 | Pao-Yu Chuang became Controller |
| Jul 19, 2019 | Jonathan P Northrup became a director |
| Jul 19, 2019 | David J. Arthur became a director |
| Jul 19, 2019 | David J. Arthur became Chief Executive Officer |
| Jul 19, 2019 | Bruce J McCreedy Jr. became a director |
| Jul 19, 2019 | Arnold C Hanish became a director |
| Jan 10, 2019 | Boston Foundation, Inc. reported in an SEC filing no longer being a 10% owner |
| Dec 21, 2018 | Christoph H Westphal reported in an SEC filing no longer being a director |
| Dec 21, 2018 | Christoph H Westphal reported in an SEC filing no longer being a 10% owner |
| Dec 20, 2018 | Boston Foundation, Inc. became a 10% owner |
| Oct 18, 2018 | Longwood Fund II, L.P. reported in an SEC filing no longer being a 10% owner |
| Jan 19, 2018 | William K. McVicar first listed as a director in an SEC filing |
| Oct 30, 2017 | Roger D Tung became a director |
| Jul 27, 2017 | William K. McVicar listed as President and CEO (previously President, R&D) in SEC filings |
| Jul 27, 2017 | Christoph H Westphal no longer listed as President and CEO in SEC filings |
| Apr 5, 2017 | William K. McVicar became President, R&D |
| Jan 20, 2017 | John P. McCabe listed as Chief Financial Officer (previously VP of Finance & Treasurer) in SEC filings |
Not reported recently (17)
- Bruce J McCreedy Jr. · Last reported as a director in an SEC filing dated Feb 22, 2024
- Jonathan P Northrup · Last reported as a director in an SEC filing dated Mar 25, 2020
- Scott Jordan · Last reported as Chief Business Officer in an SEC filing dated Feb 18, 2020
- Pao-Yu Chuang · Last reported as Controller in an SEC filing dated Sep 12, 2019
- Peter Barton Hutt · Last reported as a director in an SEC filing dated Jul 26, 2018
- Stuart A Randle · Last reported as a director in an SEC filing dated Jul 26, 2018
- Marc D Kozin · Last reported as a director in an SEC filing dated Jul 26, 2018
- Michelle Stacy · Last reported as a director in an SEC filing dated Jul 26, 2018
- Roger D Tung · Last reported as a director in an SEC filing dated Jul 26, 2018
- John P. McCabe · Last reported as Chief Financial Officer in an SEC filing dated Jun 18, 2018
- Thomas Wessel · Last reported as Chief Medical Officer in an SEC filing dated Jan 19, 2018
- Elizabeth Woo · Last reported as SVP, Investor Relations in an SEC filing dated Jan 19, 2018
- Roderick MacKinnon · Last reported as a director in an SEC filing dated Jul 27, 2017
- Jeffrey D Capello · Last reported as a director in an SEC filing dated Jul 27, 2017
- Robert J Perez · Last reported as a director in an SEC filing dated Jul 27, 2017
- Robert Hadfield · Last reported as General Counsel & Secretary in an SEC filing dated Jan 20, 2017
- Katharine Lindemann · Last reported as Chief Operating Officer in an SEC filing dated Jan 20, 2017
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.